FABP4 (Fatty Acid Binding Protein 4), also known as aP2, is a critical lipid chaperone predominantly expressed in adipocytes and macrophages. Acting as both an intracellular lipid transporter and a secreted adipokine, FABP4 sits at the intersection of metabolic disease, inflammation, and oncology. Developing therapeutics targeting FABP4—ranging from small molecule inhibitors to neutralizing monoclonal antibodies—requires highly specific reagents that can differentiate FABP4 from closely related family members while maintaining structural integrity for functional assays.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FABP4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FABP4 Recombinant Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. E. coli or HEK293 expressed to preserve native conformational epitopes. |
View FABP4 Products |
| Gene Delivery | FABP4 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction, ideal for overexpression studies and cellular lipid uptake assays. |
View FABP4 Products |
| Benchmark Ab | Anti-FABP4 Benchmark Antibody Recombinant positive control antibody for neutralization, ELISA, and Western Blot validation. |
View FABP4 Products |
| Validator | FABP4 siRNA Set Target-specific siRNA pool for target knockdown verification in macrophages and adipocytes. |
View FABP4 Products |
| Related Target A | FABP3 (Heart-type FABP) Critical homolog for counter-screening to avoid cardiotoxicity. |
View FABP3 Products |
| Related Target B | FABP5 (Epidermal FABP) Co-expressed homolog in macrophages; essential for assessing dual-inhibitor selectivity. |
View FABP5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-target Cross-reactivity (FABP3/FABP5) | Homolog panel (FABP3, FABP4, FABP5) strictly verified by Mass Spectrometry and SDS-PAGE to guarantee identity and >95% purity. |
| Lipid-Binding Assay Interference | Delipidated recombinant FABP4 proteins available, ensuring empty binding pockets for accurate small molecule binding kinetics. |
| Lack of Controls | Clinical-grade benchmark antibodies and sequence-verified siRNA included for assay standardization. |
| False Positives in Cell Assays | Endotoxin-controlled production (<1.0 EU/μg) prevents TLR4-mediated background activation in macrophage assays. |
Live FABP4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FABP4 therapeutics is intensifying, with major players shifting focus from traditional small molecule inhibitors to neutralizing monoclonal antibodies that target secreted FABP4. As first-generation therapies reach the clinic, the next wave of R&0 is targeting metabolic syndrome, non-alcoholic steatohepatitis (NASH/MASH), and cardiovascular disease complications. Because extracellular FABP4 acts as an endocrine factor promoting insulin resistance and atherosclerosis, neutralizing circulating FABP4 has emerged as a highly promising therapeutic strategy, bypassing the systemic toxicity sometimes associated with intracellular lipid-binding pocket inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Hanmi Pharm, Academic Institutions | Type 2 Diabetes, Atherosclerosis | Neutralization Assay (Need high-purity, endotoxin-controlled extracellular FABP4) |
| Small Molecule | Bristol Myers Squibb (BMS-309403), Biopharma | NASH/MASH, Obesity, Oncology | Selectivity Assay (Need FABP3 vs. FABP4 vs. FABP5 recombinant proteins for pocket binding) |
| RNA Therapeutics | Preclinical Biotechs | Cardiovascular Disease | Knockdown Validation (Need sequence-verified siRNA and stable cell lines) |